drugset / Trial / NCT06970743
A Study of BGB-16673 Compared to Investigator's Choice in Participants With Relapsed/Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma Previously Exposed to Covalent Bruton Tyrosine Kinase (BTK) Inhibitors
RandomizedParallel-groupOpen-labelTreatment
Summary
The purpose of this study is to investigate the efficacy and safety of BGB-16673 compared with investigator's choice (bendamustine plus rituximab or high-dose methylprednisolone plus rituximab) in participants with relapsed/refractory (R/R) chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL) previously exposed to covalent Bruton tyrosine kinase inhibitor(s) (cBTKi).
Timeline
- Start
- 2025-05-29
- Primary completion
- 2029-11-30
- Completion
- 2029-11-30
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | BGB-16673 | Other / unclassified | — | Oral |
| Comparator | Bendamustine | Small molecule | — | Intravenous |
| Comparator | Methylprednisolone | Other / unclassified | — | Intravenous |
| Comparator | Rituximab | Monoclonal antibody | — | Intravenous |